HTA Council Recommendation (as of 09 July 2025) The HTA Council positively recommends newborn pulse oximetry as a screening test for CCHD among asymptomatic, apparently healthy newborns for financing of DOH and/or PhilHealth. In addition to this, the HTA Council recommends that the Department of Health refer to the WHO-UNICEF technical specifications when selecting the continue reading : Newborn Pulse Oximetry as a screening test for critical congenital heart disease (CCHD) among asymptomatic, apparently healthy newborns
Japanese Encephalitis Vaccine for the prevention of japanese encephalitis among children 9 to 59 months old in high-risk areas
HTA Council Recommendation (as of 13 June 2025) The HTA Council positively recommends the government financing of both live, attenuated, recombinant, vero cell; and, inactivated adsorbed, vero cell Japanese Encephalitis vaccines to be rolled out in high risk areas (as defined by DOH), contingent on the budget and resource availability. (See below for more details) continue reading : Japanese Encephalitis Vaccine for the prevention of japanese encephalitis among children 9 to 59 months old in high-risk areas
Pneumococcal Conjugate Vaccine (PCV) for Infants less than 1 year old and children aged 13 to 23 months for catch-up immunization
HTA Council Recommendation (as of 16 May 2025) The HTA Council positively recommends the government financing of the following PCVs for infants less than 1 year old and children aged 13 to 23 months, in no particular order: Recommending the above-mentioned vaccines will provide the National Immunization Program (NIP) more options and more flexibility in continue reading : Pneumococcal Conjugate Vaccine (PCV) for Infants less than 1 year old and children aged 13 to 23 months for catch-up immunization
Ceftaroline Fosamil (600 mg powder for concentrate for solution for injection) in the Treatment of Community-Acquired Pneumonia (CAP) in Children
HTA Council Recommendation (as of 14 May 2025) The HTA Council does not recommend the government financing of ceftaroline fosamil for the treatment of community-acquired pneumonia (CAP) in the pediatric population. (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Fecal immunohistochemical test (FIT) as screening tool for colorectal cancer (CRC) among asymptomatic healthy adults, aged 45 years old and above
HTA Council Recommendation (as of 26 February 2025) The HTA Council recommends qualitative Fecal immunohistochemical test (FIT) as an annual screening test for colorectal cancer (CRC) for apparently healthy adults aged 50 years and above for financing of DOH and/or PhilHealth (See below for more details). Relevant Information Evidence and Relevant Documents Assessment History Back continue reading : Fecal immunohistochemical test (FIT) as screening tool for colorectal cancer (CRC) among asymptomatic healthy adults, aged 45 years old and above